$HBIO
HARVARD BIOSCIENCE INC

2017 Q4 Form 10-K Financial Statement

#000117184318002041 Filed on March 16, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 2016 Q4
Revenue $27.46M $77.41M $26.42M
YoY Change 3.97% -25.94% -6.89%
Cost Of Revenue $10.63M $38.24M $14.31M
YoY Change -25.74% -31.85% -7.35%
Gross Profit $11.02M $39.17M $12.11M
YoY Change -8.96% -19.1% -6.34%
Gross Profit Margin 40.13% 50.6% 45.83%
Selling, General & Admin $8.730M $32.61M $10.26M
YoY Change -14.91% -21.31% -0.39%
% of Gross Profit 79.22% 83.24% 84.76%
Research & Development $1.530M $5.645M $1.160M
YoY Change 31.9% 4.69% -24.18%
% of Gross Profit 13.88% 14.41% 9.58%
Depreciation & Amortization $930.0K $1.317M $990.0K
YoY Change -6.06% -14.03% -22.05%
% of Gross Profit 8.44% 3.36% 8.18%
Operating Expenses $10.65M $39.81M $13.23M
YoY Change -19.52% -22.58% 3.26%
Operating Profit $673.0K -$635.0K -$1.123M
YoY Change -159.93% -78.81% -1093.81%
Interest Expense -$230.0K $713.0K $170.0K
YoY Change -235.29% 11.58% -206.25%
% of Operating Profit -34.18%
Other Income/Expense, Net -$849.0K -$1.986M $135.0K
YoY Change -728.89% 2351.85% -131.11%
Pretax Income -$475.0K -$3.662M -$988.0K
YoY Change -51.92% 17.86% 207.79%
Income Tax -$464.0K -$605.0K $332.0K
% Of Pretax Income
Net Earnings $999.0K -$865.0K -$1.320M
YoY Change -175.68% -79.92% -92.3%
Net Earnings / Revenue 3.64% -1.12% -5.0%
Basic Earnings Per Share $0.03 -$0.02 -$0.04
Diluted Earnings Per Share $0.03 -$0.02 -$0.04
COMMON SHARES
Basic Shares Outstanding 34.75M shares 34.37M shares
Diluted Shares Outstanding 34.75M shares

Balance Sheet

Concept 2017 Q4 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.200M $5.200M $5.600M
YoY Change -7.14% -7.14% -16.42%
Cash & Equivalents $5.733M $5.200M $5.596M
Short-Term Investments
Other Short-Term Assets $3.709M $8.400M $4.175M
YoY Change -11.16% 7.8%
Inventory $16.85M $16.80M $19.96M
Prepaid Expenses
Receivables $13.38M $13.40M $15.75M
Other Receivables $3.700M $3.700M $4.200M
Total Short-Term Assets $47.54M $47.50M $45.47M
YoY Change 4.54% 4.4% -10.04%
LONG-TERM ASSETS
Property, Plant & Equipment $3.743M $3.700M $4.296M
YoY Change -12.87% -13.95% -27.21%
Goodwill $36.34M $38.03M
YoY Change -4.46% -5.76%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $324.0K $10.50M $128.0K
YoY Change 153.13% 707.69% -15.79%
Total Long-Term Assets $61.82M $61.90M $62.29M
YoY Change -0.76% -0.64% -10.37%
TOTAL ASSETS
Total Short-Term Assets $47.54M $47.50M $45.47M
Total Long-Term Assets $61.82M $61.90M $62.29M
Total Assets $109.4M $109.4M $107.8M
YoY Change 1.47% 1.48% -10.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.410M $4.400M $6.196M
YoY Change -28.83% -29.03% -29.45%
Accrued Expenses $3.816M $3.800M $4.550M
YoY Change -16.13% -17.39% 13.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.800M $2.800M $2.400M
YoY Change 16.67% 16.67% 0.0%
Total Short-Term Liabilities $14.04M $14.00M $14.60M
YoY Change -3.84% -4.11% -24.44%
LONG-TERM LIABILITIES
Long-Term Debt $8.983M $9.000M $11.37M
YoY Change -21.02% -21.05% -30.51%
Other Long-Term Liabilities $2.800M $2.800M $3.200M
YoY Change -12.5% -12.5% 6.67%
Total Long-Term Liabilities $8.983M $11.80M $11.37M
YoY Change -21.02% -19.18% -30.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.04M $14.00M $14.60M
Total Long-Term Liabilities $8.983M $11.80M $11.37M
Total Liabilities $28.45M $28.50M $35.57M
YoY Change -20.0% -19.94% -16.21%
SHAREHOLDERS EQUITY
Retained Earnings -$117.0M -$116.0M
YoY Change 0.81% 3.86%
Common Stock $219.2M $215.6M
YoY Change 1.7% 1.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 7.746M shares 7.746M shares
Shareholders Equity $80.90M $80.90M $72.20M
YoY Change
Total Liabilities & Shareholders Equity $109.4M $109.4M $107.8M
YoY Change 1.47% 1.48% -10.23%

Cashflow Statement

Concept 2017 Q4 2017 2016 Q4
OPERATING ACTIVITIES
Net Income $999.0K -$865.0K -$1.320M
YoY Change -175.68% -79.92% -92.3%
Depreciation, Depletion And Amortization $930.0K $1.317M $990.0K
YoY Change -6.06% -14.03% -22.05%
Cash From Operating Activities -$940.0K $1.057M $1.720M
YoY Change -154.65% -80.36% -2.82%
INVESTING ACTIVITIES
Capital Expenditures -$210.0K $890.0K -$530.0K
YoY Change -60.38% -160.14% -22.06%
Acquisitions $0.00
YoY Change
Other Investing Activities $10.00K $10.00K $1.420M
YoY Change -99.3% -99.3%
Cash From Investing Activities -$200.0K -$917.0K $890.0K
YoY Change -122.47% 1379.03% -230.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $160.0K
YoY Change -12.09%
Debt Paid & Issued, Net $4.702M
YoY Change -48.04%
Cash From Financing Activities -440.0K -$1.792M -1.210M
YoY Change -63.64% -63.19% 4.31%
NET CHANGE
Cash From Operating Activities -940.0K $1.057M 1.720M
Cash From Investing Activities -200.0K -$917.0K 890.0K
Cash From Financing Activities -440.0K -$1.792M -1.210M
Net Change In Cash -1.580M -$1.652M 1.400M
YoY Change -212.86% -464.68% -2100.0%
FREE CASH FLOW
Cash From Operating Activities -$940.0K $1.057M $1.720M
Capital Expenditures -$210.0K $890.0K -$530.0K
Free Cash Flow -$730.0K $167.0K $2.250M
YoY Change -132.44% -97.57% -8.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 us-gaap Defined Benefit Plan Actual Return On Plan Assets
DefinedBenefitPlanActualReturnOnPlanAssets
3868000 USD
CY2016 us-gaap Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss
DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
-3095000 USD
CY2016Q4 us-gaap Defined Benefit Plan Funded Status Of Plan
DefinedBenefitPlanFundedStatusOfPlan
-2962000 USD
CY2017 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
0 pure
CY2017 us-gaap Defined Benefit Plan Assumptions Used In Calculations Narrative Description
DefinedBenefitPlanAssumptionsUsedInCalculationsNarrativeDescription
The discount rate assumptions used for pension accounting reflect the prevailing rates available on high-quality, fixed-income debt instruments with terms that match the average expected duration of the Company’s defined benefit pension plan obligations. The Company uses the iBoxx AA 15yr+ index, which matches the average duration of its pension plan liability of approximately 15 years. With the current base of assets in the pension plans, a one percent increase/decrease in the discount rate assumption would decrease/increase annual pension expense by approximately $##D<pen-disc-rate-change>.
CY2016Q4 us-gaap Defined Benefit Plan Weighted Average Asset Allocations
DefinedBenefitPlanWeightedAverageAssetAllocations
1 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.1
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.84
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5022186 shares
CY2016Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.94
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.8
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1072653 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
-301520 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.29
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
-34576 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
5.56
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.56
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-81000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-381000 USD
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-958000 USD
CY2017 us-gaap Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss
DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
1674000 USD
CY2016Q4 us-gaap Defined Benefit Plan Amounts Recognized In Balance Sheet
DefinedBenefitPlanAmountsRecognizedInBalanceSheet
-2458000 USD
CY2016Q4 hbio Deferred Income Taxes On Pension Liabilities
DeferredIncomeTaxesOnPensionLiabilities
504000 USD
CY2016Q4 us-gaap Defined Benefit Pension Plan Current And Noncurrent Liabilities
DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
2962000 USD
CY2017 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
0.0243 pure
CY2015 us-gaap Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets
DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
0.0443 pure
CY2016 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
309000 USD
CY2015 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
-4000 USD
CY2015 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
4000 USD
CY2016 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
11000 USD
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
611000 USD
CY2015Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
310000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4097 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0172 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M0D
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
2755000 USD
CY2017Q4 hbio Percentage Of Outstanding Common Stock
PercentageOfOutstandingCommonStock
0.2 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.85 pure
CY2017Q4 hbio Employee Stock Purchase Plan Shares Authorized
EmployeeStockPurchasePlanSharesAuthorized
1050000 shares
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
801454 shares
CY2017Q4 hbio Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold
LenderApprovalToFundAcquisitionWithCashPromissoryNoteInExcessOfThreshold
6000000 USD
CY2017Q4 hbio Lender Approval To Fund Acquisition With Equity In Excess Of Threshold
LenderApprovalToFundAcquisitionWithEquityInExcessOfThreshold
10000000 USD
CY2009Q3 hbio Previous Approved Credit Facility
PreviousApprovedCreditFacility
20000000 USD
CY2013Q1 hbio Ddtl Threshold For Dollar For Dollar Reduction In Revolving Line
DdtlThresholdForDollarForDollarReductionInRevolvingLine
10000000 USD
CY2009Q3 hbio Interest Rate In Excess Of Libor On Credit Facility
InterestRateInExcessOfLiborOnCreditFacility
0.03 pure
CY2013Q4 hbio Transferof Delayed Draw Down Term Loan Capacity To Revolver Capacity
TransferofDelayedDrawDownTermLoanCapacityToRevolverCapacity
5000000 USD
CY2015 us-gaap Restructuring Charges
RestructuringCharges
788000 USD
CY2015 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
0 USD
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1259000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11884000 USD
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0pt;' >(b)</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0pt;' >Use of Estimates</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:27pt;' >The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of management estimates. Such estimates include the determin</font><font style='font-family:Times New Roman;font-size:10pt;' >ation and establishment of certain accruals and provisions, including those for inventory excess and obsolescence, income tax and reserves for bad debts. In addition, certain estimates are required in order to determine the value of assets and liabilities </font><font style='font-family:Times New Roman;font-size:10pt;' >associated with acquisitions, as well as the Company&#8217;s defined benefit pension obligations. Estimates are also required to evaluate the value and recoverability of existing long-lived and intangible assets, including goodwill. On an ongoing basis, the Comp</font><font style='font-family:Times New Roman;font-size:10pt;' >any reviews its estimates based upon currently available information. Actual results could differ materially from those estimates.</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ></p></div>
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19832000 USD
CY2015 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
59941000 USD
CY2015 us-gaap Gross Profit
GrossProfit
48723000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6420000 USD
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
54285000 USD
CY2017 us-gaap Gross Profit
GrossProfit
47597000 USD
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
21036000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5645000 USD
CY2017 us-gaap Restructuring Charges
RestructuringCharges
0 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
50436000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-1713000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
47698000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-101000 USD
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
210000 USD
CY2015 us-gaap Interest Expense
InterestExpense
846000 USD
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1895000 USD
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-534000 USD
CY2017 us-gaap Interest Expense
InterestExpense
713000 USD
CY2017 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
0 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-740000 USD
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1987000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15431000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1223000 USD
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2017 us-gaap Depreciation
Depreciation
1317000 USD
CY2016 us-gaap Depreciation
Depreciation
1532000 USD
CY2015 us-gaap Depreciation
Depreciation
1745000 USD
CY2017 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
12000 USD
CY2016 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 USD
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-25000 USD
CY2017 hbio Non Cash Restructuring Charge
NonCashRestructuringCharge
0 USD
CY2016 hbio Non Cash Restructuring Charge
NonCashRestructuringCharge
-27000 USD
CY2016 hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
20000 USD
CY2015 hbio Amortization Of Catalog Costs
AmortizationOfCatalogCosts
9000 USD
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-109000 USD
CY2016 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
309000 USD
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-7000 USD
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2442000 USD
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2722000 USD
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2819000 USD
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
44000 USD
CY2016 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
91000 USD
CY2015 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
86000 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1584000 USD
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-279000 USD
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
15116000 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-196000 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-566000 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1340000 USD
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
548000 USD
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1248000 USD
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1223000 USD
CY2017 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
102000 USD
CY2016 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
658000 USD
CY2015 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-755000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-918000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2413000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2577000 USD
CY2017 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
212000 USD
CY2016 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-195000 USD
CY2015 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-311000 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-736000 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
871000 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1511000 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
95000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-187000 USD
CY2016 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
727000 USD
CY2015 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1786000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1057000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5383000 USD
CY2017 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-890000 USD
CY2016 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-1445000 USD
CY2015 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
-2960000 USD
CY2017 hbio Additions To Catalog Costs
AdditionsToCatalogCosts
-39000 USD
CY2016 hbio Additions To Catalog Costs
AdditionsToCatalogCosts
-34000 USD
CY2015 hbio Additions To Catalog Costs
AdditionsToCatalogCosts
-18000 USD
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000 USD
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6000 USD
CY2017 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2016 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
CY2015 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4545000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-917000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-62000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7517000 USD
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4702000 USD
CY2016 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
9050000 USD
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
8350000 USD
CY2017 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
2750000 USD
CY2016 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
4000000 USD
CY2015 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
5800000 USD
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2015 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
32000 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
160000 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
182000 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2042000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1792000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4868000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-540000 USD
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-38000 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
137000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1148000 USD
CY2015 us-gaap Interest Paid
InterestPaid
854000 USD
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
928000 USD
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
963000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2630000 USD
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
208000 USD
CY2015 hbio Shares Withheld For Taxes Value
SharesWithheldForTaxesValue
773000 USD
CY2015 us-gaap Stockholders Equity Other Shares
StockholdersEquityOtherShares
237000 shares
CY2015 hbio Shares Withheld For Taxes
SharesWithheldForTaxes
652000 shares
CY2017 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4445000 USD
CY2016 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4606000 USD
CY2015 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4936000 USD
CY2017 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-24000 USD
CY2016 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-29000 USD
CY2015 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-85000 USD
CY2017 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
37000 USD
CY2016 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
10000 USD
CY2015 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
8000 USD
CY2016 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
252000 USD
CY2015 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
248000 USD
CY2017 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
-1200000 USD
CY2016 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
430000 USD
CY2015 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
-1029000 USD
CY2017 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1500000 USD
CY2016 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
178000 USD
CY2015 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1277000 USD
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4774000 USD
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3651000 USD
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5117000 USD
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9081000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22690000 USD
CY2016 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
52000 USD
CY2016 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
88000 USD
CY2015Q4 us-gaap Goodwill
Goodwill
40357000 USD
CY2016Q4 us-gaap Secured Debt
SecuredDebt
13746000 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11899000 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0 USD
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
0 USD
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
11899000 USD
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1772000 USD
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1468000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
580000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1105000 USD
CY2017Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0 USD
CY2016Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0 USD
CY2017Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
246000 USD
CY2016Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
193000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1953000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1784000 USD
CY2017Q4 hbio Total Accrued Expenses
TotalAccruedExpenses
4551000 USD
CY2016Q4 hbio Total Accrued Expenses
TotalAccruedExpenses
4550000 USD
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
297000 USD
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
790000 USD
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
677000 USD
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
559000 USD
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
960000 USD
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
673000 USD
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
575000 USD
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
103000 USD
CY2015 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-840000 USD
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-710000 USD
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1046000 USD
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1227000 USD
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
23000 USD
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
165000 USD
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-12000 USD
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-71000 USD
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-93000 USD
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
82000 USD
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
174000 USD
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
110000 USD
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-161000 USD
CY2016 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
-89000 USD
CY2015 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
-169000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-983000 USD
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
16401000 USD
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1000 USD
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-9000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-3129000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-3107000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-3331000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1041000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
29000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-277000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
170000 USD
CY2016Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
1336000 USD
CY2016Q4 hbio Deferred Tax Assets Operating Loss And Credits Carryforwards
DeferredTaxAssetsOperatingLossAndCreditsCarryforwards
12586000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions
631000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
3262000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
23000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20089000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17840000 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2249000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
349000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
7509000 USD
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
-5260000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
93000 USD
CY2017Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
891000 USD
CY2017Q4 hbio Deferred Tax Assets Operating Loss And Credits Carryforwards
DeferredTaxAssetsOperatingLossAndCreditsCarryforwards
8287000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Pensions
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPensions
151000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
2273000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
119000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13484000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
11447000 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2037000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
270000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
5819000 USD
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
-3782000 USD
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
62000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6744000 USD
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
171000 USD
CY2016 us-gaap Stockholders Equity Other Shares
StockholdersEquityOtherShares
302000 shares
CY2016 hbio Shares Withheld For Taxes
SharesWithheldForTaxes
296000 shares
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
196000 USD
CY2016 hbio Shares Withheld For Taxes Value
SharesWithheldForTaxesValue
185000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
95468000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
77598000 USD
CY2014Q4 us-gaap Shares Issued
SharesIssued
40309000 shares
CY2017 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
0 USD
CY2016 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
0 USD
CY2015 us-gaap Defined Benefit Plan Service Cost
DefinedBenefitPlanServiceCost
0 USD
CY2016 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
632000 USD
CY2015 us-gaap Defined Benefit Plan Interest Cost
DefinedBenefitPlanInterestCost
711000 USD
CY2017 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
663000 USD
CY2016 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
683000 USD
CY2015 us-gaap Defined Benefit Plan Expected Return On Plan Assets
DefinedBenefitPlanExpectedReturnOnPlanAssets
668000 USD
CY2017 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-362000 USD
CY2016 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-304000 USD
CY2015 us-gaap Defined Benefit Plan Amortization Of Gains Losses
DefinedBenefitPlanAmortizationOfGainsLosses
-306000 USD
CY2017 us-gaap Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments
DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
0 USD
CY2016 us-gaap Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments
DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
0 USD
CY2015 us-gaap Defined Benefit Plan Recognized Net Gain Loss Due To Curtailments
DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
0 USD
CY2017 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
223000 USD
CY2016 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
253000 USD
CY2015 us-gaap Defined Benefit Plan Net Periodic Benefit Cost
DefinedBenefitPlanNetPeriodicBenefitCost
349000 USD
CY2016 us-gaap Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
4636000 USD
CY2016 hbio Service Cost For Defined Benefit Plan
ServiceCostForDefinedBenefitPlan
0 USD
CY2016 us-gaap Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation
DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
-3654000 USD
CY2017 us-gaap Defined Benefit Plan Benefit Obligation Benefits Paid
DefinedBenefitPlanBenefitObligationBenefitsPaid
-514000 USD
CY2017 us-gaap Defined Benefit Plan Actuarial Gain Loss
DefinedBenefitPlanActuarialGainLoss
26000 USD
CY2017 us-gaap Defined Benefit Plan Actual Return On Plan Assets
DefinedBenefitPlanActualReturnOnPlanAssets
1871000 USD
CY2017 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
689000 USD
CY2015Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
15767000 USD
CY2017Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
21126000 USD
CY2017Q4 us-gaap Defined Benefit Plan Funded Status Of Plan
DefinedBenefitPlanFundedStatusOfPlan
-1154000 USD
CY2017Q4 hbio Deferred Income Taxes On Pension Liabilities
DeferredIncomeTaxesOnPensionLiabilities
196000 USD
CY2017Q4 us-gaap Defined Benefit Pension Plan Current And Noncurrent Liabilities
DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
1154000 USD
CY2017Q4 us-gaap Defined Benefit Plan Amounts Recognized In Balance Sheet
DefinedBenefitPlanAmountsRecognizedInBalanceSheet
-958000 USD
CY2015 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
341000 USD
CY2017Q4 us-gaap Noncurrent Assets
NoncurrentAssets
20100000 USD
CY2016Q4 us-gaap Noncurrent Assets
NoncurrentAssets
21767000 USD
CY2017Q4 hbio Segment Reporting Information Net Assets1
SegmentReportingInformationNetAssets1
80900000 USD
CY2016Q4 hbio Segment Reporting Information Net Assets1
SegmentReportingInformationNetAssets1
77598000 USD
CY2015 hbio Valuation Allowances And Reserves Currency Translation
ValuationAllowancesAndReservesCurrencyTranslation
-18000 USD
CY2016 hbio Valuation Allowances And Reserves Currency Translation
ValuationAllowancesAndReservesCurrencyTranslation
-19000 USD
CY2016Q4 us-gaap Revenues
Revenues
26415000 USD
CY2016Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14310000 USD
CY2016Q4 us-gaap Gross Profit
GrossProfit
12105000 USD
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
13228000 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1123000 USD
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
135000 USD
CY2016Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-988000 USD
CY2016Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
332000 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-1320000 USD
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2016 hbio Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed
MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed
0.5 pure
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33592775 shares
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33592775 shares
CY2017 us-gaap Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation
DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
1876000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20490000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16350000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1744000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1657000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1501000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1110000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1089000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1873000 USD
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
8974000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2400000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2200000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2200000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2200000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2100000 USD
CY2017Q4 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
41213000 USD
CY2017Q4 hbio Total Intangible Assets
TotalIntangibleAssets
88999000 USD
CY2016 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
-97000 USD
CY2016 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
143000 USD
CY2017Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
246000 USD
CY2017 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
-7000 USD
CY2017 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
60000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14134000 USD
CY2017 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
5621000 USD
CY2017 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-361000 USD
CY2017Q4 us-gaap Secured Debt
SecuredDebt
11748000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18904000 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14608000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
47786000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-31826000 USD
CY2016Q4 hbio Total Indefinite Lived Intangible Assets Including Goodwill
TotalIndefiniteLivedIntangibleAssetsIncludingGoodwill
39241000 USD
CY2016Q4 hbio Total Intangible Assets
TotalIntangibleAssets
84882000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1095190 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4163 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4197 pure
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0203 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0129 pure
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M28D
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2016Q2 us-gaap Gross Profit
GrossProfit
11675000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M15D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
3500000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
3497000 USD
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34211521 shares
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34211521 shares
CY2017 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
76215 shares
CY2015Q2 hbio Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan
IncreaseInNumberOfSharesAuthorizedForIssuanceUnderStockOptionAndIncentivePlan
2500000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
17508929 shares
CY2015Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
80000 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
100000 USD
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2016Q2 us-gaap Revenues
Revenues
26136000 USD
CY2016Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14461000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
12515000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-840000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
73000 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-767000 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-54000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-713000 USD
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2016 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-5065000 USD
CY2016 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-291000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
45641000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-28170000 USD
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1900000 USD
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1800000 USD
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2100000 USD
CY2015 us-gaap Revenues
Revenues
108664000 USD
CY2016Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
16252000 USD
CY2017 us-gaap Defined Benefit Plan Benefit Obligation Contributions By Plan Participant
DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
0 USD
CY2017Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months
DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
500000 USD
CY2017Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Two
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
600000 USD
CY2017Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Three
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
600000 USD
CY2017Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Four
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
600000 USD
CY2017Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Year Five
DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
700000 USD
CY2017Q4 us-gaap Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter
DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
4200000 USD
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000 USD
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000 USD
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000 USD
CY2016 hbio Current Federal And State Income Tax Expense Benefit Continuing Operations
CurrentFederalAndStateIncomeTaxExpenseBenefitContinuingOperations
170000 USD
CY2015 hbio Current Federal And State Income Tax Expense Benefit Continuing Operations
CurrentFederalAndStateIncomeTaxExpenseBenefitContinuingOperations
-4000 USD
CY2017 hbio Deferred Federal And State Income Tax Expense Benefit Continuing Operations
DeferredFederalAndStateIncomeTaxExpenseBenefitContinuingOperations
-2357000 USD
CY2015 hbio Deferred Federal And State Income Tax Expense Benefit Continuing Operations
DeferredFederalAndStateIncomeTaxExpenseBenefitContinuingOperations
15598000 USD
CY2017 hbio Deferred Income Taxes Amount
DeferredIncomeTaxesAmount
-1782000 USD
CY2016 hbio Deferred Income Taxes Amount
DeferredIncomeTaxesAmount
269000 USD
CY2015 hbio Deferred Income Taxes Amount
DeferredIncomeTaxesAmount
14758000 USD
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
285000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
406000 USD
CY2015 hbio Business Acquisition Direct Acquisition Costs In Income Statement
BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement
1200000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
313559 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
306397 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6263112 shares
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.42
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.3
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
254685 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
-237188 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
-10335 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
945000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
-413864 shares
CY2016 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
81228 shares
CY2015 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
58823 shares
CY2017Q4 hbio Incentive Stock Options Granted To Date
IncentiveStockOptionsGrantedToDate
10218057 shares
CY2016Q4 hbio Incentive Stock Options Granted To Date
IncentiveStockOptionsGrantedToDate
10218057 shares
CY2017Q4 hbio Non Qualified Stock Options Granted To Date
NonQualifiedStockOptionsGrantedToDate
13369074 shares
CY2016Q4 hbio Non Qualified Stock Options Granted To Date
NonQualifiedStockOptionsGrantedToDate
13131374 shares
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5351261 shares
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5521283 shares
CY2017Q4 hbio In The Money Stock Options Exercisable At The Reporting Date
InTheMoneyStockOptionsExercisableAtTheReportingDate
824869 shares
CY2017Q4 hbio Common Stock Market Value Per Share On Reporting Date
CommonStockMarketValuePerShareOnReportingDate
3.3
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
800000 USD
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M25D
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4000000 USD
CY2017 hbio Annualized Estimated Forfeiture Rate
AnnualizedEstimatedForfeitureRate
0 pure
CY2015 hbio Annualized Estimated Forfeiture Rate
AnnualizedEstimatedForfeitureRate
0.0806 pure
CY2017 hbio Weighted Average Estimated Black Scholes Value Of Option Grants
WeightedAverageEstimatedBlackScholesValueOfOptionGrants
1.32
CY2015 hbio Weighted Average Estimated Black Scholes Value Of Option Grants
WeightedAverageEstimatedBlackScholesValueOfOptionGrants
2.12
CY2015 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
-81000 USD
CY2015 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
-24000 USD
CY2017Q1 us-gaap Revenues
Revenues
24156000 USD
CY2017Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12657000 USD
CY2017Q1 us-gaap Gross Profit
GrossProfit
11499000 USD
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
12138000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-639000 USD
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-404000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1043000 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-1066000 USD
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2017Q4 us-gaap Revenues
Revenues
27463000 USD
CY2017Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14291000 USD
CY2017Q4 us-gaap Gross Profit
GrossProfit
13172000 USD
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
12499000 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
673000 USD
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-846000 USD
CY2017Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-173000 USD
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1172000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
999000 USD
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2017Q2 us-gaap Revenues
Revenues
25213000 USD
CY2017Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13926000 USD
CY2017Q2 us-gaap Gross Profit
GrossProfit
11287000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
11286000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-463000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-462000 USD
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-136000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-274000 USD
CY2016Q4 hbio Undistributed Foreign Earnings
UndistributedForeignEarnings
48600000 USD
CY2015Q4 hbio Undistributed Foreign Earnings
UndistributedForeignEarnings
48700000 USD
CY2017Q4 hbio Cash In Foreign Subsidiaries
CashInForeignSubsidiaries
4800000 USD
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16400000 USD
CY2017Q4 hbio Net Operating Loss Carryforwards Subject To Annual Limitation
NetOperatingLossCarryforwardsSubjectToAnnualLimitation
3300000 USD
CY2017Q4 hbio Net Operating Loss Carryforwards Annual Limitation
NetOperatingLossCarryforwardsAnnualLimitation
700000 USD
CY2015Q4 hbio Cash Held In Foreign Subsidiaries Used For Foreign Capital Improvements
CashHeldInForeignSubsidiariesUsedForForeignCapitalImprovements
300000 USD
CY2017Q4 hbio Tax Liability On Foreign Earnings Repatriated
TaxLiabilityOnForeignEarningsRepatriated
200000 USD
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2017 hbio Shares Withheld For Taxes Value
SharesWithheldForTaxesValue
243000 USD
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
140000 USD
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
190000 USD
CY2017 us-gaap Stockholders Equity Other Shares
StockholdersEquityOtherShares
489000 shares
CY2017 hbio Shares Withheld For Taxes
SharesWithheldForTaxes
131000 shares
CY2015Q4 us-gaap Shares Issued
SharesIssued
41725000 shares
CY2016Q4 us-gaap Shares Issued
SharesIssued
42187000 shares
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1772000 shares
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
375000 shares
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
143000 shares
CY2016 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-1891000 USD
CY2017 hbio Net Change In Income Tax Expense Benefit Resulting From Permanent Differences
NetChangeInIncomeTaxExpenseBenefitResultingFromPermanentDifferences
-108000 USD
CY2016 hbio Net Change In Income Tax Expense Benefit Resulting From Permanent Differences
NetChangeInIncomeTaxExpenseBenefitResultingFromPermanentDifferences
-128000 USD
CY2015 hbio Net Change In Income Tax Expense Benefit Resulting From Permanent Differences
NetChangeInIncomeTaxExpenseBenefitResultingFromPermanentDifferences
32000 USD
CY2017 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
-14000 USD
CY2017 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
-58000 USD
CY2016 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
127000 USD
CY2015 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
35000 USD
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-8000 USD
CY2017Q4 hbio Deferred Tax Liabilities Indefinite Lived Intangible Assets
DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets
3166000 USD
CY2016Q4 hbio Deferred Tax Liabilities Indefinite Lived Intangible Assets
DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets
4567000 USD
CY2017Q4 hbio Deferred Tax Liabilities Definite Lived Intangible Assets
DeferredTaxLiabilitiesDefiniteLivedIntangibleAssets
2383000 USD
CY2016Q4 hbio Deferred Tax Liabilities Definite Lived Intangible Assets
DeferredTaxLiabilitiesDefiniteLivedIntangibleAssets
2593000 USD
CY2017 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
72000 USD
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-6393000 USD
CY2015Q4 hbio Additional Paid In Capital Net Operating Loss Impact On Deferred Tax Assets
AdditionalPaidInCapitalNetOperatingLossImpactOnDeferredTaxAssets
900000 USD
CY2017 hbio Defined Benefit Plan Increase Decrease In Discount Rate Percentage
DefinedBenefitPlanIncreaseDecreaseInDiscountRatePercentage
0.001 pure
CY2017 hbio Defined Benefit Plan Increase Decrease In Asset Return Percentage
DefinedBenefitPlanIncreaseDecreaseInAssetReturnPercentage
0.001 pure
CY2017 hbio Defined Benefit Plan Increase Decrease In Discount Rate Value
DefinedBenefitPlanIncreaseDecreaseInDiscountRateValue
12000 USD
CY2017 hbio Defined Benefit Plan Increase Decrease In Asset Return Value
DefinedBenefitPlanIncreaseDecreaseInAssetReturnValue
200000 USD
CY2017 hbio Defined Benefit Plan Average Pension Plan Liability
DefinedBenefitPlanAveragePensionPlanLiability
P15Y
CY2017 hbio Defined Benefit Plan Average Remaining Work Lifetime
DefinedBenefitPlanAverageRemainingWorkLifetime
P15Y
CY2017Q4 us-gaap Shares Issued
SharesIssued
42764000 shares
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16236000 USD
CY2017Q4 us-gaap Assets
Assets
109354000 USD
CY2017Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1244000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4213000 USD
CY2017Q4 us-gaap Inventory Net
InventoryNet
21353000 USD
CY2017Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
182000 USD
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15960000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
47535000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
324000 USD
CY2017Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
2765000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5404000 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
633000 USD
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
387000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4551000 USD
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
301000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14041000 USD
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8983000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3964000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1466000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
28454000 USD
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
418000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
215134000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116030000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16658000 USD
CY2016Q4 us-gaap Treasury Stock Carrying Basis
TreasuryStockCarryingBasis
10668000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107765000 USD
CY2017Q4 us-gaap Goodwill
Goodwill
39969000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
72196000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4140000 USD
CY2015 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
93000 USD
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10284000 USD
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1042000 USD
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
10027000 USD
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9340000 USD
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
823000 USD
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9792000 USD
CY2014Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
252000 USD
CY2015Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
147000 USD
CY2016Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
193000 USD
CY2015Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
18582000 USD
CY2017Q4 us-gaap Defined Benefit Plan Weighted Average Asset Allocations
DefinedBenefitPlanWeightedAverageAssetAllocations
1 pure
CY2017Q3 us-gaap Revenues
Revenues
25050000 USD
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13411000 USD
CY2017Q3 us-gaap Gross Profit
GrossProfit
11639000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
11775000 USD
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-410000 USD
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-417000 USD
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2016Q1 us-gaap Revenues
Revenues
26963000 USD
CY2016Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14018000 USD
CY2016Q1 us-gaap Gross Profit
GrossProfit
12945000 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
13166000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-221000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-222000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-443000 USD
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
193000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-636000 USD
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
454000 USD
CY2017 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
-109000 USD
CY2017 us-gaap Valuation Allowances And Reserves Adjustments
ValuationAllowancesAndReservesAdjustments
-68000 USD
CY2017 hbio Valuation Allowances And Reserves Currency Translation
ValuationAllowancesAndReservesCurrencyTranslation
20000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5733000 USD
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
454000 USD
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42763985 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35018478 shares
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
-151000 USD
CY2017 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
62000 USD
CY2017 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
-246000 USD
CY2016 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3497000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-865000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-19039000 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.15
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5741298 shares
CY2016 hbio Weighted Average Estimated Black Scholes Value Of Option Grants
WeightedAverageEstimatedBlackScholesValueOfOptionGrants
1.21
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
43000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
-593596 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4096818 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
3.89
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.92
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.31
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.15
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.04
CY2015Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.85
CY2016 hbio Annualized Estimated Forfeiture Rate
AnnualizedEstimatedForfeitureRate
0.0841 pure
CY2015Q4 hbio Non Qualified Stock Options Granted To Date
NonQualifiedStockOptionsGrantedToDate
13088374 shares
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2015 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2015 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2088000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3078000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3608000 USD
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
-13000 USD
CY2016 us-gaap Interest Paid
InterestPaid
620000 USD
CY2016Q4 hbio Cash In Foreign Subsidiaries
CashInForeignSubsidiaries
4500000 USD
CY2015 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
0 USD
CY2016 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
1417000 USD
CY2017 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
0 USD
CY2015 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
241000 USD
CY2015 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
58000 USD
CY2017 hbio Current Federal And State Income Tax Expense Benefit Continuing Operations
CurrentFederalAndStateIncomeTaxExpenseBenefitContinuingOperations
262000 USD
CY2017 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
3149000 USD
CY2016 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
497000 USD
CY2015 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0 USD
CY2017 hbio Income Tax Reconciliation Foreign Operations Foreign Withholding Taxes
IncomeTaxReconciliationForeignOperationsForeignWithholdingTaxes
38000 USD
CY2016 hbio Income Tax Reconciliation Foreign Operations Foreign Withholding Taxes
IncomeTaxReconciliationForeignOperationsForeignWithholdingTaxes
74000 USD
CY2015 hbio Income Tax Reconciliation Foreign Operations Foreign Withholding Taxes
IncomeTaxReconciliationForeignOperationsForeignWithholdingTaxes
0 USD
CY2017 hbio Income Tax Reconciliation Foreign Tax Credits Deduction
IncomeTaxReconciliationForeignTaxCreditsDeduction
648000 USD
CY2016 hbio Income Tax Reconciliation Foreign Tax Credits Deduction
IncomeTaxReconciliationForeignTaxCreditsDeduction
1772000 USD
CY2015 hbio Income Tax Reconciliation Foreign Tax Credits Deduction
IncomeTaxReconciliationForeignTaxCreditsDeduction
0 USD
CY2017 hbio Income Tax Reconciliation Loss On Subsidiary Stock Sale
IncomeTaxReconciliationLossOnSubsidiaryStockSale
0 USD
CY2016 hbio Income Tax Reconciliation Loss On Subsidiary Stock Sale
IncomeTaxReconciliationLossOnSubsidiaryStockSale
501000 USD
CY2015 hbio Income Tax Reconciliation Loss On Subsidiary Stock Sale
IncomeTaxReconciliationLossOnSubsidiaryStockSale
0 USD
CY2017Q4 hbio Undistributed Foreign Earnings
UndistributedForeignEarnings
49200000 USD
CY2016Q4 hbio Additional Paid In Capital Net Operating Loss Impact On Deferred Tax Assets
AdditionalPaidInCapitalNetOperatingLossImpactOnDeferredTaxAssets
0 USD
CY2017 hbio Income Tax Rate Reconciliation Deductions Stock Options
IncomeTaxRateReconciliationDeductionsStockOptions
0 USD
CY2016 hbio Income Tax Rate Reconciliation Deductions Stock Options
IncomeTaxRateReconciliationDeductionsStockOptions
1600000 USD
CY2016 hbio Business Acquisition Direct Acquisition Costs In Income Statement
BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement
100000 USD
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
3000 USD
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
5000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1667000 USD
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2076000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
59000 USD
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
35000 USD
CY2017Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
400000 USD
CY2016Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
-104000 USD
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001123494
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017 dei Entity Registrant Name
EntityRegistrantName
HARVARD BIOSCIENCE INC
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Trading Symbol
TradingSymbol
HBIO
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35594802 shares
CY2017Q2 dei Entity Public Float
EntityPublicFloat
73064219 USD
CY2017Q2 hbio Non Affiliate Share Holding
NonAffiliateShareHolding
28652635 shares
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15746000 USD
CY2016Q4 us-gaap Assets
Assets
107765000 USD
CY2016Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1209000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4175000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
19955000 USD
CY2016Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
1157000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17471000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
45472000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128000 USD
CY2016Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
2372000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6196000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
500000 USD
CY2016Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
223000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4550000 USD
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
760000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14601000 USD
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11374000 USD
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6417000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
3177000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
35569000 USD
CY2016Q4 us-gaap Goodwill
Goodwill
38032000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5596000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4296000 USD
CY2017 us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0pt;' >(s)</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0pt;' >Recently I</font><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;' >ssued Accounting Pronouncements</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:22.5pt;' >In February 2016, the FASB issued ASU 2016-02, </font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;' >Leases</font><font style='font-family:Times New Roman;font-size:10pt;' >, </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >which is intended to improve financial reporting about leasing transactions. The update requires a lessee to record on the balance sheet the assets and liabilities for</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > the rights and obligations created by lease terms of more than 12&#160;months. The update is effective for fiscal years beginning after December&#160;15, 2018. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The Company has commenced the process of evaluating the requirements of the standard as well as collectin</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >g information on all its leases. The Company has not yet concluded on the impact of the adoption on its consolidated financial position, results of operations and cash flows, however, assets and liabilities will increase upon adoption for right-of-use asse</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >ts and lease liabilities.&#160;</font><font style='font-family:Times New Roman;font-size:10pt;' > The Company&#8217;s future commitments under lease obligations are summarized in Note 14.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:22.5pt;color:#000000;' >In June 2016, the FASB issued ASU 2016-13,</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >&#160;</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >Financial Instruments &#8211; Credit Losses (Topic 326), Measurement of credit losses on Financial Instrume</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >nts.</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >&#160;</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The update amends the FASB&#8217;s guidance on the impairment of financial instruments. The ASU adds to U.S. GAAP an impairment model (known as the current expected credit loss (CECL) model) that is based on expected losses rather than incurred losses. Unde</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >r the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which the FASB believes will result in more timely recognition of such losses. The ASU is effective for fiscal years beginning after December 15, 2019, includi</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >ng interim periods within those fiscal years. The Company is evaluating the impact of ASU 2016-13 on its consolidated financial statements.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >In August 2017, the FASB issued ASU 2017-12,&#160;</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >Derivatives and Hedging (Topic 815)</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >&#160;which amends the hedge accounting </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >recognition and presentation requirements in ASC 815. The Board&#8217;s objectives in issuing the ASU are to (1) improve the transparency and understandability of information conveyed to financial statement users about an entity&#8217;s risk management activities by b</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >etter aligning the entity&#8217;s financial reporting for hedging relationships with those risk management activities and (2) reduce the complexity of and simplify the application of hedge accounting by preparers. The ASU is effective for annual reporting period</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >s, including interim periods within those annual reporting periods, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period. The Company is evaluating the requirements of this guidance and has not yet determ</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >ined the impact of the adoption on its consolidated financial position, results of operations and cash flows.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:24.5pt;' >Recently Adopted Accounting Pronouncements</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:24.5pt;' >Adopted in 2017</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >In March 2016, the FASB issued ASU 2016-09,&#160;Compensation &#8211; Stock Compensation (Topic</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > 718):&#160;</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >Improvements to Employee Share-Based Payment Accounting</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >, which simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >statement of cash flows.</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >&#160;</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >The standard requires an entity to recognize all excess tax benefits and tax deficiencies as income tax benefit or expense in the income statement as discrete items in the reporting period in which they occur, and such tax benefi</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >ts and tax deficiencies are not included in the estimate of an entity&#8217;s annual effective tax rate, applied on a prospective basis. Further, the standard eliminates the requirement to defer the recognition of excess tax benefits until the benefit is realize</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >d through a reduction to taxes payable. All excess tax benefits previously unrecognized, along with any valuation allowance, should be recognized on a modified retrospective basis as a cumulative adjustment to retained earnings as of the date of adoption. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >Under ASU 2016-09, an entity that applies the treasury stock method in calculating diluted earnings per share is required to exclude excess tax benefits and deficiencies from the calculation of assumed proceeds since such amounts are recognized in the inco</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >me statement. Excess tax benefits should also be classified as operating activities in the same manner as other cash flows related to income taxes on the statement of cash flows, as such excess tax benefits no longer represent financing activities since th</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >ey are recognized in the income statement, and should be applied prospectively or retrospectively to all periods presented.</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >&#160;</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >The Company adopted ASU 2016-09 as of January 1, 2017. The Company recorded a cumulative increase in retained earnings of $0.5 mil</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >lion at the beginning of the first quarter of 2017 with a corresponding increase in deferred tax assets related to the prior years&#8217; unrecognized excess tax benefits. An equal amount of valuation allowance was also recorded against these deferred tax assets</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > with a corresponding decrease to retained earnings resulting in no net impact to retained earnings and deferred tax assets. In addition, tax deficiencies related to vested restricted stock units and canceled stock options during the year ended December 31</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >, 2017 have been recognized in the current period&#8217;s income statement.</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >&#160;</font></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >ASU 2016-09 also allows an entity to elect as an accounting policy either to continue to estimate the total number of awards for which the requisite service period will not be rendered</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > or to account for forfeitures for service based awards as they occur. An entity that elects to account for forfeitures as they occur should apply the accounting change on a modified retrospective basis as a cumulative effect adjustment to retained earning</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >s as of the date of adoption. The Company elected as an accounting policy to account for forfeitures for service based awards as they occur, and as a result, the Company recorded a cumulative effect adjustment of $0.1 million to reduce retained earnings wi</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >th a corresponding increase in additional paid in capital related to the prior years&#8217; stock-based compensation expense as required under the modified retrospective approach. The tax effect of this adjustment, which included the impact of a valuation allowa</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >nce was immaterial.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;margin-left:24.5pt;' >Adopted in 2018</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09,&#160;</font><font style='font-family:Times New Roman;font-size:10pt;font-style:italic;color:#000000;' >Revenue from Contracts with Customers,&#160;</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >a</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance within generally accepted accounting principles in the </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >United States. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or service</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >s. </font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:24.5pt;color:#000000;' >&#160;The Company has completed the process of evaluating the impact of the new standard on its consolidated financial position, results of operations and cash flows. The Company adopted this standard as of January 1, 2018 using the modified retrospective </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >approach. As part of the implementation of the standard, the Company identified its significant revenue streams, which currently consist primarily of product revenue transactions, and to a lesser extent, extended warranty transactions on certain product sa</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >les, and revenues from government contracts. The timing of recognizing revenues for these revenue streams is not expected to materially change. Additionally, no material changes to business processes, systems and controls are expected. The Company is draft</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >ing enhanced revenue disclosures which will be presented prospectively starting in the first quarter of 2018.</font></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;line-height:12pt;' ></p><p style='text-align:left;margin-top:0pt;margin-bottom:0pt;line-height:12pt;' ><font style='font-family:Times New Roman;font-size:10pt;margin-left:22.5pt;color:#000000;' >In May 2017, the FASB issued ASU 2017-09,&#160;Stock compensation (Topic 718): Scope of modification accounting&#160;which amends the scope of </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. Sp</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >ecifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The ASU is effective for annual reporting periods, including i</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >nterim periods within those annual reporting periods, beginning after December 15, 2017. </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >The Company adopted </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >this guidance </font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' >on January 1, 2018, and the new standard did not have</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > a material impact on its consolidated financial position, results of operations</font><font style='font-family:Times New Roman;font-size:10pt;color:#000000;' > and cash flows.</font><font style='font-family:Times New Roman;font-size:10pt;' >.</font></p></div>
CY2017 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
300000 USD
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5982000 USD
CY2015 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2755000 USD
CY2017 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3500000 USD
CY2016Q3 us-gaap Revenues
Revenues
25007000 USD
CY2016Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13317000 USD
CY2016Q3 us-gaap Gross Profit
GrossProfit
11690000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
12503000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-813000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-67000 USD
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-880000 USD
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
758000 USD
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2014Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
328000 USD
CY2017 hbio Business Acquisition Direct Acquisition Costs In Income Statement
BusinessAcquisitionDirectAcquisitionCostsInIncomeStatement
500000 USD
CY2017 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
1937000 USD
CY2017 hbio Minimun Percentage Of Term Loan And Delayed Draw Term Loan On Which Interest Rate Required To Be Fixed
MinimunPercentageOfTermLoanAndDelayedDrawTermLoanOnWhichInterestRateRequiredToBeFixed
0.5 pure
CY2016 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
56106000 USD
CY2016 us-gaap Gross Profit
GrossProfit
48415000 USD
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20486000 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20950000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5392000 USD
CY2016 us-gaap Restructuring Charges
RestructuringCharges
-4000 USD
CY2016 us-gaap Operating Expenses
OperatingExpenses
51412000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-2997000 USD
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
737000 USD
CY2016 us-gaap Interest Expense
InterestExpense
639000 USD
CY2016 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
0 USD
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-179000 USD
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-81000 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1229000 USD
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2016 us-gaap Revenues
Revenues
104521000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-4307000 USD
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
676000 USD
CY2016 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
1190000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
323000 USD
CY2016Q4 us-gaap Defined Benefit Plan Benefit Obligation
DefinedBenefitPlanBenefitObligation
19214000 USD
CY2016 us-gaap Defined Benefit Plan Benefit Obligation Benefits Paid
DefinedBenefitPlanBenefitObligationBenefitsPaid
-982000 USD
CY2016 us-gaap Defined Benefit Plan Benefit Obligation Contributions By Plan Participant
DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
0 USD
CY2017Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
19972000 USD
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
611000 USD
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42186827 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34441320 shares
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
7745507 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34753325 shares
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34753325 shares
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.24
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.93
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.48
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
-488570 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
-85527 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1298371 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
237700 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
-410883 shares
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
3.05
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.49
CY2016 us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
-484000 USD
CY2017Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.95
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1796927 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.69
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3780244 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
419000 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
218792000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116967000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10676000 USD
CY2017Q4 us-gaap Treasury Stock Carrying Basis
TreasuryStockCarryingBasis
10668000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109354000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
80900000 USD
CY2017Q2 hbio Lender Approval To Fund Acquisition With Cash Promissory Note In Excess Of Threshold
LenderApprovalToFundAcquisitionWithCashPromissoryNoteInExcessOfThreshold
6000000 USD
CY2017Q2 hbio Lender Approval To Fund Acquisition With Equity In Excess Of Threshold
LenderApprovalToFundAcquisitionWithEquityInExcessOfThreshold
10000000 USD
CY2016 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
50000 USD
CY2017Q4 us-gaap Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year
DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
700000 USD
CY2017Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
21100000 USD
CY2016Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
19200000 USD
CY2018Q1 invest Derivative Notional Amount
DerivativeNotionalAmount
36000000 USD
CY2018Q1 hbio Advance Line Of Credit Facility
AdvanceLineOfCreditFacility
4800000 USD
CY2018Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
14500000 USD
CY2018Q1 us-gaap Long Term Debt
LongTermDebt
11900000 USD
CY2018Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
64000000 USD
CY2017 us-gaap Cumulative Effect On Retained Earnings Before Tax1
CumulativeEffectOnRetainedEarningsBeforeTax1
0 USD
CY2016 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
291000 USD
CY2015 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
370000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
406000 USD
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
59000 USD
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
406000 USD
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
53000 USD
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
30000 USD
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
500000 USD
CY2017Q4 hbio Tax Credit Carryforward Used
TaxCreditCarryforwardUsed
8000000 USD
CY2015 hbio Netimpactof U Satechanges
NetimpactofUSatechanges
0 USD
CY2016 hbio Netimpactof U Satechanges
NetimpactofUSatechanges
0 USD
CY2017 hbio Netimpactof U Satechanges
NetimpactofUSatechanges
2521000 USD
CY2017 hbio Impact Of Adoption Of Asu2016 09
ImpactOfAdoptionOfAsu2016-09
-486000000 USD
CY2016 hbio Impact Of Adoption Of Asu2016 09
ImpactOfAdoptionOfAsu2016-09
0 USD
CY2015 hbio Impact Of Adoption Of Asu2016 09
ImpactOfAdoptionOfAsu2016-09
0 USD
CY2015 hbio Netimpactofforeignratechanges
Netimpactofforeignratechanges
89000 USD
CY2016 hbio Netimpactofforeignratechanges
Netimpactofforeignratechanges
30000 USD
CY2017 hbio Netimpactofforeignratechanges
Netimpactofforeignratechanges
0 USD
CY2017 hbio Lossonahn
Lossonahn
93000 USD
CY2016 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
39000 USD
CY2017 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
61000 USD

Files In Submission

Name View Source Status
0001171843-18-002041-index-headers.html Edgar Link pending
0001171843-18-002041-index.html Edgar Link pending
0001171843-18-002041.txt Edgar Link pending
0001171843-18-002041-xbrl.zip Edgar Link pending
exh1043_a1.jpg Edgar Link pending
exh1043_c1.jpg Edgar Link pending
exh_1015.htm Edgar Link pending
exh_1043.htm Edgar Link pending
exh_1044.htm Edgar Link pending
exh_1045.htm Edgar Link pending
exh_211.htm Edgar Link pending
exh_231.htm Edgar Link pending
exh_232.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_322.htm Edgar Link pending
f10k_031618.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hbio-20171231.xml Edgar Link completed
hbio-20171231.xsd Edgar Link pending
hbio-20171231_cal.xml Edgar Link unprocessable
hbio-20171231_def.xml Edgar Link unprocessable
hbio-20171231_lab.xml Edgar Link unprocessable
hbio-20171231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R100.htm Edgar Link pending
R101.htm Edgar Link pending
R102.htm Edgar Link pending
R103.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
R99.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stockprice.jpg Edgar Link pending